Literature DB >> 16270039

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.

R McClure, M Mai, T Lasho.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16270039     DOI： 10.1038/sj.leu.2404007

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  28 in total

1.  Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation.

Authors:  Elizabeth C Wolstencroft; Katy Hanlon; Lorna W Harries; Graham R Standen; Alexander Sternberg; Sian Ellard
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

2.  Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Zeev Estrov; Gautam Borthakur; Jorge Cortes; Srdan Verstovsek
Journal:  Leuk Res       Date:  2012-04-02       Impact factor: 3.156

3.  A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide.

Authors:  Barbara Denys; Hakim El Housni; Friedel Nollet; Bruno Verhasselt; Jan Philippé
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

Review 4.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

5.  Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.

Authors:  Christopher B Benton; Maria Tanaka; Catherine Wilson; Sherry Pierce; Lingsha Zhou; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2015-02-02       Impact factor: 3.156

6.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

7.  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  A Quintás-Cardama; W Tong; H Kantarjian; D Thomas; F Ravandi; S Kornblau; T Manshouri; J E Cortes; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

8.  Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.

Authors:  Paul Collier; Keyur Patel; Paul Waeltz; Mark Rupar; Rajyalakshmi Luthra; Phillip C C Liu; Gregory Hollis; Reid Huber; Srdan Verstovsek; Timothy C Burn
Journal:  Genet Test Mol Biomarkers       Date:  2013-03-28

9.  Significance of cytogenetic abnormalities in patients with polycythemia vera.

Authors:  Matjaz Sever; Alfonso Quintás-Cardama; Sherry Pierce; Lingsha Zhou; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-04-17

10.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.